Hodgkin lymphoma
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Who can joinAdults
Age18–50 years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
1 hospital in India taking patients for this trial.
Tata Memorial HospitalMumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Directions ↗
Registry summary (technical)
The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).
Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
NCT04638790 on ClinicalTrials.gov
Last updated on the registry 27 Sep 2024 · read by us 20 Oct 2026